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Background: Although there have been considerable advances in the study of dengue virus, no vaccines or
anti-dengue drugs are currently available for humans. Therefore, new approaches are necessary for the development
of potent anti-dengue drugs. Natural antimicrobial peptides (AMPs) with potent antiviral activities are potential
hits-to-leads for antiviral drug discovery. We performed this study to identify and characterise the inhibitory potential of
the latarcin peptide (Ltc 1, SMWSGMWRRKLKKLRNALKKKLKGE) against dengue virus replication in infected cells.
Results: The Ltc 1 peptide showed a significantly inhibitory effect against the dengue protease NS2B-NS3pro at
37°C, a physiological human temperature, (IC50, 12.68 ± 3.2 μM), and greater inhibitory effect was observed at 40°C,
a temperature similar to a high fever (IC50, 6.58 ± 4.1 μM). A greater reduction in viral load (p.f.u./ml) was observed
at simultaneous (0.7 ± 0.3 vs. 7.2 ± 0.5 control) and post-treatment (1.8 ± 0.7 vs. 6.8 ± 0.6 control) compared to the
pre-treatment (4.5 ± 0.6 vs. 6.9 ± 0.5 control). Treatment with the Ltc 1 peptide reduced the viral RNA in a
dose-dependent manner with EC50 values of 8.3 ± 1.2, 7.6 ± 2.7 and 6.8 ± 2.5 μM at 24, 48 and 72 h, respectively.
Conclusions: The Ltc 1 peptide exhibited significant inhibitory effects against dengue NS2B-NS3pro and virus
replication in the infected cells. Therefore, further investigation is necessary to develop the Ltc 1 peptide as a new
anti-dengue therapeutic.
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Dengue is a viral disease caused by four serotypes of the
Flavivirus genus [1] and is prevalent in tropical and sub-
tropical countries, ranging from Southeast Asia to the
Americas [2]. Over 390 million people are infected with
dengue virus (DENV) annually in over 100 counties,
resulting in approximately 12000 deaths [3]. In Malaysia,
the fatality rate of dengue infection is approximately 3.6%
based on the total number of dengue infections. The ma-
jority of deaths caused by dengue infection occur after the
mild infection develops into severe haemorrhagic fever
and dengue shock syndrome [4]. In addition to the global
health problem caused by dengue infection, it also has an* Correspondence: rothan@um.edu.my
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unless otherwise stated.economic burden. The estimated cost of dengue infection
is approximately US$ 950 million per year, which is higher
than hepatitis B and Japanese encephalitis in Southeast
Asia [5].
DENV is an enveloped virus with a positive stranded
RNA genome of approximately 11 kb in length that
encodes a single polypeptide. The host cell furin and the
viral NS2B-NS3 serine protease NS2B-NS3pro cleave
the viral polyprotein at different positions to release viral
structural and non-structural proteins [6-9]. Therefore,
the viral NS2B-NS3pro is a potential target for the design
and development of antiviral drugs [10,11]. NS2B acts as
necessary a co-factor for the optimal catalytic activity of
NS3 [10,12]. NS2B-NS3pro consists of 185 residues from
the N-terminal of the NS3 protein and the central 44 resi-
dues of the hydrophilic domain of NS2B [12,13].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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currently, no effective vaccine or antiviral therapeutics
is available [14,15]. It is difficult to develop anti-dengue
treatments because of the incidence of the antibody-
dependent enhancement due to the existence of four
dengue serotypes, the unavailability of an actual animal
model [16,17] and the nature of the dengue protease, a
promising target for dengue inhibitor development,
which possesses a flat and hydrophilic active site that
decreases the possibility of finding potent inhibitors to
develop as antiviral therapeutics [18]. These facts accen-
tuate the need for new approaches to develop potent
anti-dengue drugs.
Natural antimicrobial peptides (AMPs) are produced in
the majority of living organisms as protection against
various pathogens, including viruses. We hypothesise that
AMPs that possess potent antiviral activities may be con-
sidered as hits-to-leads for developing new antiviral drugs.
Therefore, the objective of this study was to identify and
characterise the inhibitory potential of the latarcin peptide
(Ltc 1, SMWSGMWRRKLKKLRNALKKKLKGE) against
dengue virus replication in human cells. Ltc 1 is one of ap-
proximately seven latarcin peptides, which are produced
in the venom gland of Lachesana tarabaeve, a central
Asian spider. Recent studies showed considerable anti-
microbial activities of the latarcin peptides against bacteria
and yeast [19-21]. In particular, the Ltc 1 peptide showed
moderate haemolytic activity and significant antimicrobial
activity compared to the other latarcin analogues [20].
However, there is a paucity of available data on the anti-
viral activities of Ltc 1 peptide. This study demonstrates
for the first time significant inhibition by Ltc 1 against
dengue NS2B-NS3pro and dengue virus replication in
HepG2 cells.
Methods
Virus propagation in mosquito cells and titration
HepG2 cells with passage number less than 60 were
maintained in DMEM medium supplemented with 10%
FBS and incubated at 37°C in 5% CO2. HepG2 cells were
used to study the peptide cytotoxicity and antiviral activ-
ity. Dengue virus serotype-2 (DENV2) was first propa-
gated in C6/36 cells. The DENV2-infected cells that
showed cytopathic effects (CPE) were lysed with a freeze
and thaw cycle. The culture medium was then centrifuged
at 1800 rpm for 10 min to remove the cell debris, filtered
(0.2 μm), portioned into aliquots and stored at -80°C until
use. The viral titre of the DENV2 suspension was
established by serial dilutions on Vero cells using a
plaque assay.
Peptide synthesis
The Ltc 1 peptides were manufactured chemically using
standard solid-phase peptide synthesis with a Symphonyparallel synthesiser (Protein Technologies, Tucson, AZ,
USA) as previously described [22]. Briefly, the aqueous
phase of the peptide synthesis was lyophilised to yield
the crude peptide. The identity of the crude peptide was
confirmed by LC-MS, and purification of the crude pep-
tide was performed by RP-HPLC (Agilent 1200 series,
USA). The identity of the 98% pure purified peptide was
confirmed by LC-MS (Shimadzu LC/MS 2020, single quad,
Japan). The purified peptide was then lyophilised using a
Savant AES 2000 Automatic Environmental SpeedVac sys-
tem. To prepare 2 mM pure peptide, 6.14 mg lyophilised
peptide was dissolve into 1 ml filtered-deionised water for
use as a stock solution.
Protein-protein docking
The interaction between the Ltc 1 peptide and dengue
NS2B-NS3pro was identified by protein-protein dock-
ing study. The Protein Data Bank (PDB) files of Ltc 1
(2PCO) and NS2BNS3pro (4M9F) were used in rigid
global docking using an available online server (FireDoc,
http://bioinfo3d.cs.tau.ac.il/FireDock/refs.html) as described
previously [23,24]. The results of the protein-protein
docking were further analysed using Discovery Studio
software version 3.5.
ELISA binding of Ltc 1 to dengue NS2B-NS3pro
Enzyme-linked immunosorbent assay (ELISA) was used to
examine the binding affinity of Ltc 1 to dengue NS2B-
NS3pro. Increasing concentrations of purified dengue
NS2B-NS3pro (0, 20, 30 and 50 nM/well) in carbonate/bi-
carbonate buffer (Sigma, USA) were bound to black 96-
well plate with transparent bottom at 4°C overnight in
triplicates. The wells were blocked with PBS containing
0.05% Tween 20 (PBS-T) plus 0.5% BSA for 1 h at room
temperature and washed three times with PBS-T. Increas-
ing concentrations of the Ltc 1 peptide labeled with FITC
fluorescence dye (0, 0.1, 0.5, 1, 5, 10, 20, 30, 50 nM)
were prepared in PBS-T plus BSA; 100 μl of each dilu-
tion of the Ltc 1 bound to plates for 3 h on ice in dark
place. After the plates were washed, the fluorescence
signals of bound Ltc 1 were detected using Tecan Infin-
ite M200 Pro fluorescence spectrophotometer (Tecan
Group Ltd., Switzerland).
Dengue NS2B-NS3 protease (NS2B-NS3pro) assay
The NS2B-NS3pro assay was performed to examine
whether the Ltc 1 peptide inhibits the DENV2 serine
protease [12,25]. Briefly, a single chain NS2B (G4-T-G4)
NS3pro was produced as a recombinant protein in E.
coli as previously described [22]. The end point reaction
mixture was performed in black 96-well plates, which
contained 2 μM recombinant NS2B-NS3pro, 100 μM
fluorogenic peptide substrate (Boc-Gly-Arg-Arg-AMC)
and varying concentrations of the Ltc 1 peptide (0.1 to
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total volume of 200 μl. The reaction mixtures without
peptide, substrate with the peptides, enzyme and differ-
ent concentrations of the peptides were used as con-
trols. Thereafter, all reaction mixtures were incubated at
either 37°C or 40°C for 30 min, and the substrate was
added to the specific reaction mixtures and incubated at
the same temperatures for an additional 30 min. Mea-
surements were performed in triplicate using a Tecan
Infinite M200 Pro fluorescence spectrophotometer (Tecan
Group Ltd., Switzerland). Substrate cleavage was normal-
ised against the buffer only (control) at an emission
wavelength of 440 nm with excitation at 350 nm. The
fluorescence values obtained with the no-inhibitor control
(0.0 μM peptide) were set at 100%, and those in the pres-
ence of peptide were calculated as a percentage of the
control using non-linear regression in GraphPad Prism
(version 5.01) software. The IC50 was calculated from
nonlinear regression fitting of the signal vs. concentra-
tion data points to the standard dose–response equation
Y = Bottom + (Top − Bottom)/(1 + 10^((X − LogIC50))). In
this equation, X is the log of the compound concentra-
tion, Y is the response signal, and the bottom and top
refer to the plateaus of the sigmoid response curve. All
assays were performed in triplicate and repeated twice.
The inhibition percentage was calculated using the fol-
lowing formula:
% DENV2 protease activity ¼
100−
intensity of enzyme activity–intensity left after inhibitionð Þ
intensity of enzyme activity
 
 100
Ltc 1 peptide cytotoxicity
The cytotoxicity of the Ltc 1 peptides was evaluated by
determining the maximal non-toxic dose (MNTD) and
the 50% cytotoxic concentration (CC50) of the cells using
the Non-Radioactive Cell Proliferation assay (Promega,
USA) according to the manufacturer’s instructions. The
peptide concentration of 25 μM showed 80% cell viabil-
ity and was considered the MNTD value, assuming that
approximately 80% of the cells were healthy. Vero cells
were seeded at 1×104 cells/well in triplicate under opti-
mal conditions (37°C, 5% CO2 in a humidified incuba-
tor) in 96-well plates with blank controls (media only)
and cell controls (cells only). After an overnight incuba-
tion, the cells were treated with increasing concentra-
tions of Ltc 1 peptide (0, 4, 8, 16, 32, 64 and 120 μM)
with DMEM medium supplemented with 2% FBS and
the cell culture was analysed after 72 h. The percentage
of cell viability was calculated as follows: 100 - (absorb-
ance of treated cells/absorbance of untreated cells) × 100.
The MNTD and CC50 values were calculated from the
dose-response curves.Real Time Cell Proliferation Assay (RTCA assay)
This assay was performed to test the real time effects of
the Ltc 1 peptide on cell viability. Cell proliferation was
measured using the xCELLigence Real-Time Cellular
Analysis (RTCA) system (Roche, Germany) as described
previously [26]. Cell viability and growth were moni-
tored continuously after applying increasing concentra-
tions of the Ltc 1 peptide (0, 12.5, 25, 50, 100, 150, 200,
250 μM). Briefly, the background measurements were
recorded after adding 100 μl culture medium to the
wells. Next, the cells were seeded at a density of 1 × 104
cell/well in a 16-well plate with electrodes for 18 h to
allow the cells to grow to log phase. The cells were
treated with different concentrations of peptide dissolved
in cell culture medium and continuously monitored for
up to 100 h. The cell sensor impedance was expressed as
an arbitrary unit named the cell index. The cell index
was recorded every 5 minutes using a RTCA analyser.
To eliminate variation between the wells, the cell index
values were normalised to the value at the beginning of
the treatment.
Treatment of DENV-infected cells with the Ltc 1 peptide
To infect the HepG2 cells with DENV2, the cells were
cultured in 24-well plates (1.5 × 105 cells/well) for 24 h
at 37°C and 5% CO2. The virus supernatant was added
to the cells at a MOI of 2, followed by incubation for 1 h
with gentle shaking every 15 min for optimal virus to
cell contact. The cells were washed twice with fresh
serum-free DMEM after removal of the virus super-
natant. Then, fresh complete DMEM containing 25 μM
Ltc 1 peptide was added to the cultures and incubated
for 72 h. The HepG2 cells were then collected, and the
virus particles and expression level of the viral NS1 pro-
tein were examined using immunostaining and western
immunoblotting.
Time-of-addition assay
This assay was performed to identify the mode of anti-
viral activity of the Ltc 1 peptide against DENV2 entry,
replication and release from the infected cells. Three in-
dependent experiments were performed in triplicate for
pre-, simultaneous and post-infection treatments. HepG2
cells were grown in a 24-well tissue culture plate (1.5 ×
105 cells/well), incubated 24 h under optimal conditions
and infected with DENV2 at an MOI of 2. For pre-
treatment infection, 25 μM peptide was added to the cells
before virus inoculation and incubated for 24 h. After re-
moval of the old medium containing the peptide, the
DENV2 supernatant was added, followed by incubation
for 1 h with gentle shaking every 10 min for optimal virus
to cell contact. The virus supernatant was removed and
the cells were washed twice with fresh serum-free DMEM
medium to remove the residual virus. Fresh complete
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bated for 72 h at 37°C, supplemented with 5% CO2. Iden-
tical applications were performed for the simultaneous
treatment, except the peptide was mixed with the virus
supernatant and incubated at 37°C for 1 h, and then inoc-
ulated onto the HepG2 cells. The post-treatment infection
was performed after inoculation of the HepG2 cells with
DENV2, and complete DMEM medium with the Ltc 1
peptide was then added. The cultures including the pep-
tide were incubated for 72 h at 37°C and 5% CO2, and
three wells of infected cells in each experiment were
maintained without treatment as controls. The cell super-
natants were collected and stored at −80°C for viral load
determination using a plaque formation assay.
Dose-response assay
This assay was performed to evaluate the 50% effective
concentration (EC50) of the Ltc 1 peptide against DENV2.
HepG2 cells were grown in six-well microplates (1.5 × 106
cells/well) for 24 h in quadruplicate experiments. The cell
culture media were removed and the cells were washed
three times with PBS. Then, fresh medium containing the
virus supernatant was added at MOI of 2, followed by in-
cubation for 1 h with gentle shaking every 15 min. The
viral residues were removed by washing with PBS, and ser-
ial dilutions of the Ltc 1 peptide (0, 2.5, 5, 10, 20, 40,
80 μM) were added. The cultures including the peptide
were incubated for 72 h at 37°C and 5% CO2. The cell
supernatants were collected and stored at −80°C for viral
load determination using viral RNA and were quantified
using one step qReal time-PCR.
Virus quantification by plaque formation assay
To determine the virus yield after treatment with differ-
ent concentrations of peptide, the culture supernatants
were collected and serially diluted to reduce the effects
of the drug residues. A 10-fold serial dilution of medium
supernatant was added to new Vero cells grown in 24-well
plates (1.5 × 105 cells) and incubated for 1 hr at 37°C. The
cells were then overlaid with DMEM medium containing
1.1% methylcellulose. The viral plaques were stained with
crystal violet dye after a five-day incubation. The virus ti-
tres were calculated according to the following formula:
Titre pfu=mlð Þ ¼ number of plaques volume of
diluted virus added to the well
dilution factor of the virus used
infect to the well in which the
plaques were enumerated:
Western blot
Cells lysates were prepared for immunoblotting against
dengue viral antigen using ice-cold lysis buffer. Theamount of protein in the cell lysates was quantified to
ensure equal loading (20 μg) of the western blot gels
using the 2-D Quant Kit (GE Healthcare Bio-Sciences,
USA) according to the manufacturer’s instructions. The
separated proteins were transferred onto nitrocellulose
membranes and then blocked with blocking buffer. The
membrane was incubated overnight with anti-DENV2
antibody specific to the viral NS1 protein (Abcam, UK,
Cat. no. ab41616) and an anti-beta actin antibody (Abcam,
UK, Cat. no. ab8226). After washing three times, the mem-
branes were incubated with anti-mouse IgG conjugated to
horseradish peroxidase (Dako, Denmark) at 1:1,000 for
two h. Horseradish peroxidase substrate was added to
for colour development.
Indirect immunostaining
To examine the efficacy of the Ltc 1 peptide for reducing
viral particles, HepG2 cells were grown on cover slips in
6-well plates and infected with DENV2 at an MOI of 2.
The DENV2-infected cells were then treated with 25 μM
peptide for 24 h. The cells were washed three times with
PBS to remove the peptide residues and then fixed with
ice-cold methanol for 15 min at -20°C. After washing, the
cells were incubated with coating buffer for 1 h at room
temperature. A mouse antibody specific to the dengue en-
velop glycoprotein (Abcam, UK, Cat. no. ab41349) was
added, and the cells were incubated overnight at 4°C. The
cells were washed three times with PBS and incubated for
30 min with an anti-mouse IgG labelled with FITC fluor-
escent dye (Invitrogen, USA, Cat. no. 62-6511). To stain
the cell nuclei, Hoechst dye was added (Invitrogen, USA,
Cat. no. H1399) for the last 15 min of the incubation.
Viral RNA quantification
The DENV2 copy number was quantified in the culture
supernatants using one-step quantitative real-time PCR.
Known copies of the viral RNA were 10-fold serially di-
luted to generate a standard curve. The viral RNA was
extracted using the QIAmp viral RNAmini kit (QIA-
GEN, Germany), and the qRT-PCR was performed using
a SYBR Green Master Kit (Qiagen, Germany). Triplicate
reactions were performed for each sample, and a no
template control was included as a negative control. Ab-
solute quantification was performed using an ABI7500
machine (Applied Biosystems, Foster City, CA). The re-
sults were analysed using Sequence Detection Software
Version 1.3 (Applied Biosystems, Foster City, CA). The
percentage of viral inhibition (%) was calculated as fol-
lows: 100 – (viral copy number of treated cells/viral copy
number of untreated cells) × 100.
Statistical analysis
All the assays were performed in triplicate, and the
statistical analyses were performed using GraphPad
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CA). P values <0.05 were considered significant. The
error bars are expressed as ± SD.
Results
The inhibitory potential of the Ltc 1 peptide against the
DENV2 protease NS2B-NS3pro
The results of the global rigid complementary docking
showed that the Ltc 1 peptide bound the dengue NS2B-
NS3pro near the active site (Figure 1A and 1B). The bind-
ing affinity depends on the hydrophobic interaction of four
leucine residues and two tryptophan residues of the Ltc 1
peptide with the other hydrophobic residues of NS2B-
NS3pro (Figure 1C and 1D). Therefore, a dengue NS2B-
NS3pro assay was performed to confirm the docking
findings that identified the possible interaction between the
Ltc 1 peptide and the dengue NS2B-NS3 protease.
Dengue NS2B-NS3pro was produced in E. coli as a re-
combinant protein, and its activity was evaluated using a
fluorescent peptide substrate. After the optimisation
steps, the results of this assay showed that the peptide
exhibited significant dose-dependent inhibition of dengue
NS2B-NS3pro (Figure 2A). The Ltc 1 peptide showed sig-
nificant binding affinity to purifies dengue NS2B-NS3pro
as evinced by ELISA binding assay (Figure 2B). The peptide
showed higher inhibition of the dengue NS2B-NS3pro at a
high fever-like human temperature (40°C) compared toFigure 1 Docking of Ltc 1 peptide with dengue NS2B-NS3pro. (A) and
using the FirDock online server showing the position of the Ltc 1 peptide
(C) and (D) The results of Ltc 1 - dengue NS2B-NS3pro binding show the h
the Ltc 1 peptide (red) with the other hydrophobic residues of NS2B-NS3pnormal physiologic human temperature (37°C). The inhibi-
tory concentration of 50% of enzyme activity (IC50) was
6.58 ± 4.1 at 40°C compared to 12.68 ± 3.2 μM at 37°C
(Figure 2C and 2D).
The effect of the Ltc 1 peptide on cell proliferation and
assessment of antiviral activity
The cytotoxic effect of Ltc 1 peptide on cell viability was
measured using a non-radioactive cell proliferation assay.
The CC50 value of the Ltc 1 peptide obtained via the opti-
misation steps was estimated to be approximately 52.51 ±
3.6 μM as shown in Figure 3A. The Ltc 1 peptide induces
cellular changes that lead to cell apoptosis [21]. This activ-
ity may decrease the formation of plaques leading to a
false interpretation of antiviral activity. To clarify this
issue, we examined the effects of increasing concentra-
tions of peptide on real time cell proliferation using the
Real-Time Cellular Analysis (RTCA) system. The results
showed that the effects of the peptide on cell proliferation
were insignificant at 25 μM for 110 h because the cell
index was similar to the untreated control cells. Cell
proliferation was significantly decreased at 50 μM after
66 h of incubation of the HepG2 cells with the peptide
(Figure 3B).
Concentrations higher than 50 μM peptide were toxic
to the cells at all time-points of the RTCA assay. There-
fore, a concentration of 25 μM was identified as the(B) The results of the global rigid complementary docking performed
(red) bound to the dengue NS2BNS3pro (grey) near the active site.
ydrophobic interaction of the four leucine and tryptophan residues of
ro (yellow).
Figure 2 Inhibitory effect of Ltc 1 peptides against dengue NS2B-NS3pro. The recombinant dengue NS2B (G4-T-G4) NS3pro was produced
as a recombinant protein in E. coli. (A) The kinetic assay plot for the inhibition of NS2BNS3pro from DENV2 by the Ltc 1 peptide. This assay was
performed using increasing concentrations of inhibitor while all other conditions were kept constant. The data were analysed using the Michaelis-Menten
model with a nonlinear regression curve fit in Graph Pad Prism (version 5.01) software. The concentrations of peptide were 0, 5, 10, 20, and
40 μM. (B) ELISA binding of Ltc 1 to dengue NS2B-NS3pro. Increasing concentrations of purified dengue NS2B-NS3pro (0, 20, 30 and 50 nM/
well) were bound to black 96-well plate with transparent bottom. The Ltc 1 peptide labeled with FITC fluorescence dye (0, 0.1, 0.5, 1, 5, 10, 20,
30, 50 nM) were prepared in were bound to plates for 3 h on ice in dark place. the fluorescence signals of bound Ltc 1 were detected after
washing steps using fluorescence spectrophotometer. (C) Determination of the IC50 value of the Ltc 1 peptide at normal physiologic human
temperature (37°C). (D) Determination of the IC50 value of Ltc 1 peptide at the temperature of a human with a high fever (40°C).
Rothan et al. BMC Microbiology 2014, 14:140 Page 6 of 10
http://www.biomedcentral.com/1471-2180/14/140maximal non-toxic dose (MNTD) of the Ltc 1 peptide
used in the following experiment to evaluate the antiviral
activity of the Ltc 1 peptide. The antiviral activity of the
Ltc 1 peptide was initially evaluated by immunostaining
and western blot targeting the DENV2 NS1 protein. The
results showed a significant reduction of viral particles
after treatment with the Ltc 1 peptide (Figure 3C). This
result was further confirmed by western blot analysis that
showed significant reduction in the expression of the viral
NS1 protein after treatment of the infected cells with pep-
tide. This result was normalised to beta-actin as an en-
dogenous gene to eliminate loading errors (Figure 3D).
Determination of antiviral inhibitory dose
Quantitative real-time PCR was used to determine the
viral copy numbers in the infected cells after treatment
with the Ltc 1 peptide. The infected cells were treated
with increasing concentrations of the Ltc 1 peptide for 24,
48 and 72 h. The Ltc 1 peptide showed dose-dependent
inhibition of DENV2 replication in HepG2 cells. However,
the results showed insignificant effects for the time points
on peptide activity (Figure 4). The inhibitory effects of the
Ltc 1 peptide were dependent on increasing concentra-
tions of the peptide at the three time points. The Ltc 1peptide inhibited DENV2 replication at EC50 values of
8.3 ± 1.2 μM for 24 h, 7.6 ± 2.7 μM for 48 h and 6.8 ±
2.5 μM for 72 h (Figure 4).
The mode of inhibition
The antiviral activity of the Ltc 1 peptide was further
verified by plaque formation assay that showed different
inhibitory effects of the peptide against virus entry and
replication in infected cells. The Ltc 1 peptide showed
significant inhibitory effects at a pre-treatment, simul-
taneous and post-treatment compared to the untreated
cells. However, the antiviral activity for the simultaneous
and post-treatment was significantly higher than the pre-
treatment (Figure 4A). The viral load (pfu/ml) was signifi-
cantly (p < 0.001) reduced at pre-treatment (4.5 ± 0.6) com-
pared to the untreated cells (6.9 ± 0.5). In addition, a
significant decrease (p < 0.0001) in viral load was observed
for the simultaneous treatment (0.7 ± 0.3 vs. 7.2 ± 0.5 con-
trol) and post-treatment (1.8 ± 0.7 vs. 6.8 ± 0.6 control) as
shown in Figure 5A and 5B.
Discussion
We performed this study to identify and characterise the
inhibitory potential of the latarcin peptide (Ltc 1) against
Figure 3 Effect of the Ltc 1 peptide on cells proliferation and viral replication in HepG2 cells. (A) The cytotoxic effect of the Ltc 1 peptide
on cell viability was measured by non-radioactive cell proliferation assay. (B) The effect of the Ltc 1 peptide on cell proliferation was measured
with the xCELLigence Real-Time Cellular Analysis (RTCA) system. Cell viability and growth were monitored continuously after applying increasing
concentrations of the Ltc 1 peptide (0 (cyan), 12.5 (purple), 25 (dark green), 50 (magenta), 100 (orange), 150 (blue), 200 (green), and 250 μM (red)).
(C) The effect of the Ltc 1 peptide on virus replication in infected cells. Viral particles were labelled with FITC fluorescence dye using indirect
immunostaining, and the cell nuclei were stained with Hoechst. The figure shows a significant reduction of viral particles after peptide treatment.
(D) Western blot analysis of the DENV2 NS1 protein expression level normalised to beta-actin as a reference cell protein (L1, untreated control;
L2, DENV2-infected cells treated with Ltc 1 peptide).
Figure 4 Determination of viral inhibitory dose of the Ltc 1
peptide by RT-qPCR. Serial concentrations of the Ltc 1 peptide
(0, 2.5, 5, 10, 20, 40, and 80 μM) were incubated with HepG2 cells
infected with DENV for 72 h. The viral RNA was quantified by
one-step qRT-PCR. The results showed a dose-dependent reduction
in viral copy number after treatment with the Ltc 1 peptide for 24,
48 and 72 h.
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the protein-protein docking study showed that the Ltc 1
peptide bound to the NS3 by hydrophobic residue inter-
actions of the peptide, primarily Leu 11, 14, 18 and Trp
3 and 7 that interact with the surrounding hydrophobic
residues of NS3 (Leu 28, Phe 30, Trp 50, Val 154 and
Tyr 161). The binding of Ltc 1 to NS3 may effectively
inhibit binding of the substrate to the active site or de-
crease the contribution of the NS2B co-factor active site
formation. This observations were further considered by
ELISA binding assay that showed significant binding af-
finity of Ltc 1 peptide to dengue NS2B-NS3pro.
The result of this study was further verified using a den-
gue NS2B-NS3pro assay that showed significant inhibition
by the Ltc 1 peptide against dengue protease. Dengue
NS2B-NS3pro cleaves the viral polyprotein at the posi-
tions between the capsid, NS2A-NS2B, NS2B-NS3, NS3-
NS4A and NS4B-NS5, which lead to the release of mature
individual viral structural (S) and non-structural (NS) pro-
teins [6-9]. Therefore, inhibition of dengue NS2B-NS3pro
may directly lead to inhibition of the post-translational
processing of the viral polyprotein and subsequent virus
replication [10,11].
Figure 5 Mode of action of the Ltc 1 peptide against DENV2 infection. (A) The DENV2 viral load for the pre-, simultaneous and post-infection
treatments with the latarcin peptide. The viral load (pfu/ml) was significantly reduced for the pre-treatment (4.5 ± 0.6 vs. 6.9 ± 0.5 control), simultaneous
(0.7 ± 0.3 vs. 7.2 ± 0.5 control) and post-treatment (1.8 ± 0.7 vs. 6.8 ± 0.6 control) (two-way ANOVA with Bonferroni post-test). (B) The viral loads in the
infected HepG2 cells of the pre-, simultaneous and post-infection treatments were quantified and calculated based on plaque formation in Vero cells
after a five-day incubation.
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NS2B-NS3pro in the low micromolar range (IC50 values
of 12.68 μM at 37°C and 6.58 μM at 40°C). We hypothe-
sise that the activity of the dengue protease decreased at
the high fever temperature (40°C) because of the in-
stability of the structural complex. Therefore, the Ltc 1
peptide showed higher inhibition, which is an approxi-
mately one fold reduction in the IC50 value compared to
the inhibitory potential at 37°C. The activity of the
NS2B-NS3pro primarily depends on the interaction be-
tween NS3 with the cofactor NS2B, which stabilises the
enzyme structure and contributes to the formation of
the active site [27,28].
Previous studies reported various inhibitors against
dengue protease, including standard serine protease inhibi-
tors [29], substrate based inhibitors [30], and non-substrate
based inhibitors [31,32]. For example, aprotinin, a 58
amino acid protein, showed the highest inhibitory effect
against the dengue protease at picomolar levels compared
to the other standard serine protease inhibitors [33]. The
peptidic α-keto amide [30] and cyclopeptide inhibitors
[34] showed significant inhibition against dengue NS2B-
NS3pro at micromolar dose ranges compared to the
other peptidic inhibitors. In addition, the non-substrate
based inhibitors, such as small molecule inhibitors,
showed significant inhibitory activities at low micromolarconcentrations against the flavivirus proteases [31,32]. Al-
though several of these compounds are potent inhibitors
of the dengue NS2b-NS3 protease, some showed poor sta-
bility in solution. Furthermore, several studies did not use
cell-based assays to evaluate the toxicity and antiviral effi-
cacy of the identified compounds [18]. The nature of the
dengue protease, which possesses a flat and hydrophilic
active site, decreases the possibility of identifying potent
inhibitors to develop as antiviral therapeutics [18]. Based
on the results of this study, we postulate that the hydro-
phobic residues of Ltc 1 are important for stabilising the
binding to the hydrophilic active site of the dengue
protease.
In this study, the inhibitory potential of the Ltc 1 pep-
tide against the dengue protease was further verified
using cell based assays. Previously, other characteristics
of the latarcin family peptides, such as anti-neoplastic
cells activities [21], were examined. The latarcin peptides
can alter the lipid bilayers of the cell membrane, may in-
duce the apoptosis of mammalian cells [21]. Because of
this, the possible effect of the Ltc 1 peptide on cell pro-
liferation was removed to avoid false interpretation of
the antiviral activity. Subsequently, the antiviral activity
of the Ltc 1 peptide was evaluated at the doses with min-
imal effects on cell proliferation as determined by MTT
assay and Real-Time Cellular Analysis (RTCA). The
Rothan et al. BMC Microbiology 2014, 14:140 Page 9 of 10
http://www.biomedcentral.com/1471-2180/14/140results of the immunostaining and western blot analyses
showed that the Ltc 1 peptide significantly reduced the
viral particles and non-structural protein NS1 in DENV-
infected cells. Furthermore, the results of the time-of-
addition assay showed that the Ltc 1 peptide inhibited
dengue virus replication at both the simultaneous and
post-treatments compared to the pre-treatment. The
mechanism of antimicrobial activity of the latarcin pep-
tides depends on the helix-hinge-helix structure that is
important for lysing bacterial cell membranes [35,36].
This finding emphasised that the direct incubation of
DENV with the Ltc 1 peptide during the simultaneous
treatment may led to lysis of the viral particles by the
peptide. The results of the post-treatment and dose-
response assays showed that the viral load was signifi-
cantly deceased after treatment with the Ltc 1 peptide.
Based on this finding, we hypothesise that the Ltc 1
peptide may interrupt the dengue life cycle in HepG2
cells during post-translational processing of the poly-
protein by inhibiting the dengue serine protease. This
inhibition may hinder flavivirus replication and virion
assembly, as evidenced by the lack of infectious virion
production in mutants carrying inactivating viral prote-
ases [13]. However, other α-helical peptides, similar to
Ltc 1, have significant inhibitory effects against HIV-1
because of an actual interference with the virus assem-
bly stage of the viral life cycle [37]. Therefore, other
mechanisms may be responsible for the observed ef-
fects, such as the interruption of virus assembly and re-
lease from the infected cells because of Ltc 1 interaction
with other viral or host cell proteins; however, this war-
rants additional studies.
Conclusions
The Ltc 1 peptide exhibited significant inhibition of the
dengue protease and virus replication in HepG2 cells.
Therefore, Ltc1 may act as a lead structure for develop-
ing therapies against DENV.
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